French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug
Summary
STRASBOURG, France, Jan. 23, 2023 (GLOBE NEWSWIRE) -- AdipoPharma, a French biotech company developing a novel and promising type 2 diabetes drug, announced today that it has successfully secured Series A funding. We are excited to start clinical trials this year with the first drug specifically targeting insulin resistance in adipocytes.AdipoPharmas novel approach to diabetes has already created a buzz around a disease that has not seen a single new, therapeutic development in more than a decade. We look forward to seeing the first clinical read-outs in the coming months.Newton Biocapital was joined by Good Growth Capital of Charleston, SC.Isabelle Pelletier-Bressac, founder and CEO of the French consulting firm AttLeva Conseils, served as financial advisor. PATAS, a therapeutic peptide, is the result of this research and is the first representative of a new class of drugs called Adipeutics.PATAS has been shown to restore healthy lipid biosynthesis in adipocytes in diseased animal models and should be the first diabetes drug to have significant beneficial effects on insulin resistance, type 2 diabetes, pancreatic beta cell plaque removal, liver steatosis and fibrosis correlated with decreased ceramide levels.AdipoPharma SAS is based in Strasbourg, France, with a U.S. office in Pittsburgh. NBCs diversified team of experts and its presence in Japan/Europe enable NBC to identify and select the most promising companies based on the outstanding research ecosystem in those two regions.